Replies to post #198552 on Biotech Values

[ghmm]

SKP.L

Thanks. Skyepharma is one I looked at briefly a couple years ago when sentiment was really down but (unfortunately) didn't look close enough. As I recall they had one (potential) big product and a bunch of little ones. I will have to take a closer look again.

[mcbio]

LGND -

Not so sure about the significance of their royalties for the BACE program (they got it from the Pharmacopeia merger). Would be surprised if it is bigger then 2%.

And I would actually be surprised if royalties aren't a lot higher than 2%. This isn't analogous to their Captisol licensing deals where they are just applying their tech to other companies' drugs. I assume the BACE was a NCE discovered at PCOP which LGND ultimately acquired rights to. As such, they should be entitled to much better economics (at least mid-single digits) one would think.

Edit: I take the aforementioned back given what I found was discussed (see following replies also) in: #msg-77512312. So, not a NCE at PCOP but they aided in the discovery of the BACE so really hard to know for sure exactly where the royalty winds up at.